Skip to main content
. 2022 Feb 2;6:e2100267. doi: 10.1200/PO.21.00267

FIG 3.

FIG 3.

OS for patients treated with an anti–PD-1/L1-based regimen. Among all 121 patients treated, median OS was as follows: pathogenic POLE mutation 29.5 months, VUS NR, and benign 11.6 months; pathogenic versus benign P < .001 (A). Among the 82 patients who received an immunotherapy-only regimen: pathogenic 29.5 months, VUS NR, benign 6.8 months; pathogenic versus benign P < .001. Patients with pathogenic POLE mutations had greater median OS compared to patients with benign mutations when adjusting for number of comutations (≥ 10 v < 10: HR, 0.10 [95% CI, 0.03 to 0.40], P = .001; ≥ 20 v < 20: HR, 0.10 [95% CI, 0.03 to 0.41], P = .001) or MSI status (HR, 0.14; 95% CI, 0.03 to 0.81; P = .028) (B). (C) OS from time of diagnosis for all 453 patients with POLE mutations including patients who did not receive anti–PD-1/L1 therapy. Median OS was as follows: pathogenic POLE mutation NR, VUS 8.0 years, and benign 3.4 years; pathogenic versus benign P < .001. NR, not reached; OS, overall survival; PD-1, programmed death 1; PD-L1, programmed death ligand-1; VUS, variant of unknown significance.